½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1536756

»ý¸í°úÇÐ ºÐ¾ß AI ½ÃÀå

Artificial Intelligence (AI) in Life Sciences Market

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BCC Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ »ý¸í°úÇÐ ºÐ¾ß AI ½ÃÀå ±Ô¸ð´Â 2023³â 80¾ï ´Þ·¯, 2024³â 98¾ï ´Þ·¯¿¡¼­ ¿¹Ãø ±â°£ µ¿¾È 27.9%ÀÇ CAGRÀ» ±â·ÏÇϸç 2029³â ¸»¿¡´Â 335¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

AI ¼ÒÇÁÆ®¿þ¾î ºÎ¹®Àº 2024³â 65¾ï ´Þ·¯¿¡¼­ ¿¬Æò±Õ 30.4% ¼ºÀåÇØ 2029³â ¸»¿¡´Â 247¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. AI ¼­ºñ½º ºÎ¹®Àº 2024³â 32¾ï ´Þ·¯¿¡¼­ ¿¬Æò±Õ 22.1% ¼ºÀåÇØ 2029³â ¸»¿¡´Â 88¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ »ý¸í°úÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¿µÇâ¿äÀÎ ¹× ½ÃÀå ±âȸ ºÐ¼®, ½ÅÈï ±â¼ú ¹× ±â¼ú °³¹ß µ¿Çâ, ½ÃÀå ±Ô¸ð ÃßÁ¤ ¹× ¿¹Ãø, °¢ ºÎ¹®º°¡¤Áö¿ªº° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ ÀüÇص帳´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå Àü¸Á
  • Á¶»ç ¹üÀ§
  • ½ÃÀå °³¿ä

Á¦2Àå ½ÃÀå °³¿ä

  • °³¿ä
  • Drug DiscoveryÀÇ AI
  • ºÐÀÚÁø´ÜÀÇ AI
  • ÀÓ»óÁø´ÜÀÇ AI
  • ÀÓ»ó½ÃÇèÀÇ AI
  • Á¤¹ÐÀÇ·áÀÇ AI

Á¦3Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ½ÃÀå °úÁ¦

Á¦4Àå ½Å±â¼ú°ú °³¹ß

  • ÀÓ»ó½ÃÇè
  • ÀÓ»ó½ÃÇè(»óȲº°)
  • ÀÓ»ó½ÃÇè(¿¬±¸º°)
  • Ãëµæ ƯÇã

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®

  • ¼¼ºÐÈ­ ³»¿ª
  • ½ÃÀå ºÐ¼® : Á¦Ç°º°
  • ¼¼°è
  • ¼ÒÇÁÆ®¿þ¾î
  • ¼­ºñ½º
  • ½ÃÀå ºÐ¼® : ¿ëµµº°
  • ½ÃÀå ºÐ¼®°ú ¿¹Ãø
  • Drug Discovery
  • ÀÓ»ó ¹× ºÐÀÚÁø´Ü
  • ÀÓ»ó½ÃÇè
  • Á¤¹ÐÀÇ·á¿Í ¸ÂÃãÇü ÀÇ·á
  • ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
  • ½ÃÀå ºÐ¼®°ú ¿¹Ãø
  • CRO
  • ¿¬±¸ ¼¾ÅÍ¡¤Çмú±â°ü
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Áö¿ªÀû ³»¿ª
  • ½ÃÀå ºÐ¼® : Áö¿ªº°
  • ¼¼°è
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ±âŸ Áö¿ª

Á¦6Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷°ú Á¦Ç°
  • Àü·« ºÐ¼®
  • M&A
  • ÀÚ±Ý Á¶´Þ

Á¦7Àå ºÎ·Ï

  • Á¶»ç ¹æ¹ý
  • Á¤º¸ Ãâó
  • µÎ¹®ÀÚ¾î
  • Á¤ÀÇ/ºÐ·ù
  • ±â¾÷ °³¿ä
  • AICURE
  • APIXIO
  • ATOMWISE INC.
  • BENEVOLENTAI
  • ENLITIC INC.
  • NUMEDII INC.
  • RECURSION
  • ZEBRA TECHNOLOGIES CORP.
ksm 24.08.23

The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.

The global market for AI in life sciences software is estimated to grow from $6.5 billion in 2024 to $24.7 billion by the end of 2029, at a CAGR of 30.4% from 2024 to 2029.

The global market for AI in life sciences services is estimated to grow from $3.2 billion in 2024 to $8.8 billion by the end of 2029, at a CAGR of 22.1% from 2024 to 2029.

Report Scope:

This report aims to comprehensively study the market size of global artificial intelligence (AI) in the life sciences. Current and historical market revenues can be estimated based on products, applications, end users, and regions.

Report Includes:

  • 26 data tables and 35 additional tables
  • Analyses of trends in the global market for AI in life sciences, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
  • Estimates of the current market size and revenue prospects, along with a market share analysis based on product segment, application, end user and region
  • Facts and figures pertaining to the market dynamics, current and emerging technologies, regulatory scenario and the expected impact of macroeconomic factors
  • Identification of the AI products and technologies with the highest commercial potential, and their relevant applications in life sciences, specifically precision medicine and personalized healthcare
  • Overview of ESG developments and sustainability trends, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices
  • Review of patent activity and key patent grants
  • An analysis of the industry structure, including companies' market shares, merger and acquisition activity, and venture funding outlook
  • Profiles of the leading companies, including AiCure LLC., Apixio Inc., Atomwise Inc., BenevolentAI and NuMedii Inc.

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Overview
  • Artificial Intelligence in Drug Discovery
  • Artificial Intelligence in Molecular Diagnostics
  • Artificial Intelligence in Clinical Diagnostics
  • Artificial Intelligence in Clinical Trials
  • Artificial Intelligence in Precision Medicine

Chapter 3 Market Dynamics

  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Market Challenges

Chapter 4 Emerging Technologies and Developments

  • Introduction
  • Clinical Trials
  • Clinical Trials, by Status
  • Clinical Trials, by Study
  • Granted Patents

Chapter 5 Market Segmentation Analysis

  • Segmentation Breakdown
  • Market Analysis, by Product
  • Global
  • Software
  • Services
  • Market Analysis, by Application
  • Market Analysis and Forecast
  • Drug Discovery
  • Clinical and Molecular Diagnostics
  • Clinical Trials
  • Precision and Personalized Medicine
  • Market Analysis, by End User
  • Market Analysis and Forecast
  • Contract Research Organizations
  • Research Centers and Academic Institutes
  • Pharmaceutical and Biotechnology Companies
  • Geographic Breakdown
  • Market Analysis, by Region
  • Global
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 6 Competitive Intelligence

  • Top Players and Products
  • Strategic Analysis
  • Mergers and Acquisitions
  • Funding

Chapter 7 Appendix

  • Methodology
  • Sources
  • Acronyms
  • Definitions/Taxonomy
  • Company Profiles
  • AICURE
  • APIXIO
  • ATOMWISE INC.
  • BENEVOLENTAI
  • ENLITIC INC.
  • NUMEDII INC.
  • RECURSION
  • ZEBRA TECHNOLOGIES CORP.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦